{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:42:47Z","timestamp":1791499367737,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2002,4]]},"DOI":"10.1053\/snuc\/2002.31025","type":"journal-article","created":{"date-parts":[[2002,8,24]],"date-time":"2002-08-24T23:46:10Z","timestamp":1030232770000},"page":"110-122","source":"Crossref","is-referenced-by-count":336,"title":["Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience"],"prefix":"10.1053","volume":"32","author":[{"given":"Roelf","family":"Valkema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem H.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wout A.P.","family":"Breeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.M.","family":"Kooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieternella J.","family":"Lugtenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank H.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boen L.R.","family":"Kam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter W.","family":"de Herder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Stridsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lindemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Ensing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Krenning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/snuc\/2002.31025_bib1","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/0024-3205(91)90052-D","article-title":"[111In-DTPA-D-Phe1]-Octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation","volume":"49","author":"Bakker","year":"1991","journal-title":"Life Sci"},{"key":"10.1053\/snuc\/2002.31025_bib2","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients","volume":"20","author":"Krenning","year":"1993","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc\/2002.31025_bib3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1749-6632.1994.tb17300.x","article-title":"Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history","volume":"733","author":"Krenning","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"10.1053\/snuc\/2002.31025_bib4","first-page":"1514","article-title":"Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors","volume":"41","author":"Janson","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc\/2002.31025_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00006231-199803000-00013","article-title":"Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy","volume":"19","author":"De Jong","year":"1998","journal-title":"Nucl Med Commun"},{"key":"10.1053\/snuc\/2002.31025_bib6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1139\/o89-098","article-title":"The radiation dose to cells in vitro from intracellular indium-111","volume":"67","author":"McLean","year":"1989","journal-title":"Biochem Cell Biol"},{"key":"10.1053\/snuc\/2002.31025_bib7","first-page":"652","article-title":"Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide","volume":"33","author":"Krenning","year":"1992","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc\/2002.31025_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/snuc\/2002.31025_bib9","first-page":"1022","article-title":"Imaging with octreoscan: Haste makes waste","volume":"26","author":"van Uden","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc\/2002.31025_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1677\/joe.0.1390329","article-title":"Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: Development of a specific radioimmunoassay for chromogranin A and its fragments","volume":"139","author":"Stridsberg","year":"1993","journal-title":"J Endocrinol"},{"key":"10.1053\/snuc\/2002.31025_bib11","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1054\/bjoc.2000.1677","article-title":"Chromogranin A and the alpha-subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma","volume":"84","author":"Guignat","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1053\/snuc\/2002.31025_bib12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1053\/snuc\/2002.31025_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000051856","article-title":"Natural history of neuroendocrine enteropancreatic tumors","volume":"62","author":"Mignon","year":"2000","journal-title":"Digestion"},{"key":"10.1053\/snuc\/2002.31025_bib14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/028418699432022","article-title":"Health-related quality of life in patients with endocrine tumours of the gastrointestinal tract","volume":"38","author":"Larsson","year":"1999","journal-title":"Acta Oncol"},{"key":"10.1053\/snuc\/2002.31025_bib15","article-title":"Quality of life in patients with gastrointestinal tumours","author":"Larsson","year":"2001"},{"key":"10.1053\/snuc\/2002.31025_bib16","first-page":"94","article-title":"In situ radiotherapy with 111In-pentetreotide: Initial observations and future directions","volume":"4","author":"McCarthy","year":"1998","journal-title":"Cancer J Sci Am"},{"key":"10.1053\/snuc\/2002.31025_bib17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000051861","article-title":"Treatment of neuroendocrine GEP tumours with somatostatin analogues: A review","volume":"62","author":"Arnold","year":"2000","journal-title":"Digestion"},{"key":"10.1053\/snuc\/2002.31025_bib18","first-page":"19P","article-title":"In-111-octreotide therapy: Phase I\u2013II trial","volume":"40","author":"Cornelius","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc\/2002.31025_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/028418699431465","article-title":"Treatment with high dose [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors: Evaluation of therapeutic and toxic effects","volume":"38","author":"Tiensuu","year":"1999","journal-title":"Acta Oncol"},{"key":"10.1053\/snuc\/2002.31025_bib20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00006231-200001000-00016","article-title":"Toxicity of high-activity 111In-octreotide therapy in patients with disseminated neuroendocrine tumours","volume":"21","author":"Caplin","year":"2000","journal-title":"Nucl Med Commun"},{"key":"10.1053\/snuc\/2002.31025_bib21","first-page":"88","article-title":"In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives","volume":"44","author":"McCarthy","year":"2000","journal-title":"Q J Nucl Med"},{"key":"10.1053\/snuc\/2002.31025_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(05)78355-0","article-title":"Yttrium-90-labelled somatostatin-analogue for cancer treatment","volume":"351","author":"Otte","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/snuc\/2002.31025_bib23","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC: First clinical results","volume":"26","author":"Otte","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc\/2002.31025_bib24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1089\/cbr.1999.14.477","article-title":"Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide: Preliminary report in cancer patients","volume":"14","author":"Paganelli","year":"1999","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/snuc\/2002.31025_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000051858","article-title":"Octreo Ther: Ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy","volume":"62","author":"Smith","year":"2000","journal-title":"Digestion"},{"key":"10.1053\/snuc\/2002.31025_bib26","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study","volume":"12","author":"Waldherr","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/snuc\/2002.31025_bib27","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s002590100490","article-title":"Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide","volume":"28","author":"Paganelli","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc\/2002.31025_bib28","first-page":"1025P","article-title":"Safety and efficacy of [Y-90-DOTA,Tyr(3)]octreotide (Y-90-SMT487: OCTREOTHERTM) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study","volume":"28","author":"Valkema","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc\/2002.31025_bib29","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s002590100574","article-title":"[177Lu-DOTA0,Tyr3]octreotate: Comparison with [111In-DTPA0]octreotide in patients","volume":"28","author":"Kwekkeboom","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc\/2002.31025_bib30","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<767::AID-IJC17>3.0.CO;2-T","article-title":"Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver","volume":"81","author":"Slooter","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1053\/snuc\/2002.31025_bib31","first-page":"125P","article-title":"Peptide receptor radionuclide therapy (PRRT) using somatostatin analogs","volume":"42","author":"Capello","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc\/2002.31025_bib32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1259\/0007-1285-59-697-45","article-title":"The long-term hazards of the treatment of thyroid cancer with radioiodine","volume":"59","author":"Edmonds","year":"1996","journal-title":"Br J Radiol"},{"key":"10.1053\/snuc\/2002.31025_bib33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/bjc.1973.142","article-title":"Induction of leukemia by 131-I treatment of thyroid carcinoma","volume":"28","author":"Brincker","year":"1973","journal-title":"Br J Cancer"},{"key":"10.1053\/snuc\/2002.31025_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0140-6736(92)92421-B","article-title":"Leukaemia incidence after iodine-131 exposure","volume":"340","author":"Hall","year":"1992","journal-title":"Lancet"},{"key":"10.1053\/snuc\/2002.31025_bib35","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/bjc.1997.130","article-title":"Leukaemias and cancers following iodine-131 administration for thyroid cancer","volume":"75","author":"de Vathaire","year":"1997","journal-title":"Br J Cancer"},{"issue":"suppl 1","key":"10.1053\/snuc\/2002.31025_bib36","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1530\/eje.0.143S009","article-title":"Somatostatin receptors in the haematopoietic system","volume":"143","author":"Oomen","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"10.1053\/snuc\/2002.31025_bib37","series-title":"Brenner and Rector's The Kidney","first-page":"1200","article-title":"Acute renal failure","author":"Brady","year":"1995"},{"key":"10.1053\/snuc\/2002.31025_bib38","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1210\/endo.139.1.5661","article-title":"The localization of messenger ribonucleic acids for somatostatin receptors 1, 2, and 3 in rat testis","volume":"139","author":"Zhu","year":"1998","journal-title":"Endocrinology"},{"key":"10.1053\/snuc\/2002.31025_bib39","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1210\/jcem.83.9.5121","article-title":"Serum inhibin B as a marker of spermatogenesis","volume":"83","author":"Pierik","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/snuc\/2002.31025_bib40","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s002590050535","article-title":"Testicular function after radioiodine therapy for thyroid carcinoma","volume":"27","author":"Wichers","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc\/2002.31025_bib41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","article-title":"Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms","volume":"68","author":"Moertel","year":"1991","journal-title":"Cancer"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299802800290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299802800290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T20:21:13Z","timestamp":1555014073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299802800290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["S0001299802800290"],"URL":"https:\/\/doi.org\/10.1053\/snuc\/2002.31025","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}